Q4 Earnings Estimate for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for shares of Illumina in a research report issued to clients and investors on Monday, November 4th. Leerink Partnrs analyst P. Souda now anticipates that the life sciences company will earn $0.89 per share for the quarter, down from their prior forecast of $0.93. The consensus estimate for Illumina’s current full-year earnings is $3.62 per share. Leerink Partnrs also issued estimates for Illumina’s Q1 2025 earnings at $0.84 EPS, Q2 2025 earnings at $0.97 EPS, Q3 2025 earnings at $1.08 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.14 EPS and FY2026 earnings at $4.92 EPS.

A number of other equities research analysts have also recently weighed in on the company. HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. Royal Bank of Canada increased their price target on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday. Daiwa Capital Markets upgraded Illumina from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $120.00 to $154.00 in a research report on Friday, August 16th. Finally, Barclays increased their price objective on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $162.18.

Illumina Stock Down 2.0 %

ILMN opened at $151.83 on Thursday. Illumina has a 1-year low of $89.00 and a 1-year high of $156.66. The stock’s fifty day simple moving average is $137.27 and its 200 day simple moving average is $123.12. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The stock has a market cap of $24.19 billion, a PE ratio of -15.24 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 6.36% and a negative net margin of 36.10%. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter in the prior year, the business posted $0.33 EPS. The business’s revenue was down 3.5% compared to the same quarter last year.

Institutional Trading of Illumina

Several large investors have recently bought and sold shares of ILMN. Primecap Management Co. CA boosted its stake in Illumina by 462.5% in the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after buying an additional 1,997,010 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Illumina by 305.0% during the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after purchasing an additional 1,118,747 shares in the last quarter. Capital World Investors boosted its stake in shares of Illumina by 41.1% during the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after purchasing an additional 801,814 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Illumina during the second quarter valued at about $77,628,000. Finally, Swedbank AB acquired a new stake in shares of Illumina during the first quarter valued at about $99,682,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.